Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 420Precursor Cell Lymphoblastic Leukemia-Lymphoma 126Neoplasms, Plasma Cell 74Recurrence 70Lymphoma 57Leukemia 54Neoplasms 46Immunoglobulin Light-chain Amyloidosis 38Burkitt Lymphoma 37Vomiting 36Lymphoma, Mantle-Cell 32Lymphoma, Large B-Cell, Diffuse 31Nausea 29Lymphoma, Non-Hodgkin 28Breast Neoplasms 22Waldenstrom Macroglobulinemia 21Lymphoma, Follicular 21Hodgkin Disease 21Leukemia, Lymphocytic, Chronic, B-Cell 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Neoplasm Metastasis 17Prostatic Neoplasms 16Lymphoma, Extranodal NK-T-Cell 16Amyloidosis 16Leukemia, Myeloid, Acute 15Smoldering Multiple Myeloma 14Lymphoma, B-Cell, Marginal Zone 13Lung Neoplasms 11Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell 10

Interventions

Dexamethasone 3daratumumab 2Lenalidomide 2pomalidomide 1nirogacestat 1belantamab mafodotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Corneal Diseases × Dexamethasone × Clear all
NCT05280275 2023-12-01

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Hellenic Society of Hematology

Phase 1/2 Unknown
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05573802 2023-10-24

A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma

Hellenic Society of Hematology

Phase 1/2 Recruiting
36 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

NCT05581875 2022-10-17

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory

Hellenic Society of Hematology

Phase 1/2 Not yet recruiting
48 enrolled
Plasma cell

Blood Protein Disorders, Corneal Diseases, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡